Importantly, Ziady’s group recently showed that the broadly used CFTR modulators VX-809 (Lumacaftor) and VX-661 (Tezacaftor) significantly increase Nrf2 activity after correction of CFTR expression in primary epithelial cells of CF patients with homozygous F508del mutations (Borcherding et al., 2019). Here, CFTR is linked to cystic fibrosis.